CCL2 and glioblastoma: Current studies have confirmed that reducing excessive ROS production in glioblastoma cells can decrease pro-inflammatory factors IL-8 and MCP-1, thereby preventing the establishment of a harmful pro-inflammatory tumor microenvironment (Tewari et al., 2009).